A. Shibuya, M. Watanabe, Y. Fujita, K. Saigenji, S. Kuwao et al., An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care, 1998.
DOI : 10.2337/diacare.21.12.2140

E. Kraegen, D. James, A. Jenkins, and L. Storlien, A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high fat feeding of rats, Metabolism, vol.38, issue.11, pp.1089-1093, 1989.
DOI : 10.1016/0026-0495(89)90045-0

M. Lee, P. Miles, M. Khoussheed, K. Gao, A. Moossa et al., Metabolic Effects of Troglitazone on Fructose-Induced Insulin Resistance in the Rat, Diabetes, vol.43, issue.12, pp.1435-1439, 1994.
DOI : 10.2337/diab.43.12.1435

P. Miles, K. Higo, O. Romeo, M. Lee, K. Rafaat et al., Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance, Diabetes, vol.47, issue.3, pp.395-400, 1998.
DOI : 10.2337/diabetes.47.3.395

Y. Iwamoto, T. Kuzuya, A. Matsuda, T. Awata, S. Kumakura et al., Effect of New Oral Antidiabetic Agent CS-045 on Glucose Tolerance and Insulin Secretion in Patients with NIDDM, Diabetes Care, vol.14, issue.11, pp.1083-1086, 1991.
DOI : 10.2337/diacare.14.11.1083

S. Suter, J. Nolan, P. Wallace, B. Gumbiner, and J. Olefky, Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects, Diabetes Care, vol.15, issue.2, pp.193-203, 1992.
DOI : 10.2337/diacare.15.2.193

J. Chehade and A. Mooradian, A Rational Approach to Drug Therapy of Type 2 Diabetes Mellitus, Drugs, vol.6, issue.6285, pp.95-113, 2000.
DOI : 10.2337/diacare.20.7.1183

C. Wang, R. Weisel, P. Liu, P. W. Fedack, and S. Verma, Glitazones and Heart Failure: Critical Appraisal for the Clinician, Circulation, vol.107, issue.10, pp.1350-1354, 2003.
DOI : 10.1161/01.CIR.0000054675.30348.9A

M. Hanefeld and G. Belcher, Safety profile of pioglitazone, Int J Clin Pract, vol.121, pp.27-31, 2001.

N. Niemeyer and L. Janney, Thiazolidinedione-Induced Edema, Pharmacotherapy, vol.49, issue.1, pp.924-933, 2002.
DOI : 10.1001/jama.283.13.1695

M. Thomas and S. Lloyd, Pulmonary Edema Associated with Rosiglitazone and Troglitazone, Annals of Pharmacotherapy, vol.159, issue.1, pp.123-127, 2001.
DOI : 10.1038/clpt.1981.154

E. Wooltorton, Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure, CMAJ, vol.166, issue.2, p.219, 2002.

P. Raskin, M. Rendell, M. Riddle, J. Dole, M. Freed et al., A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 Diabetes, Diabetes Care, vol.24, issue.7, pp.1226-1258, 2001.
DOI : 10.2337/diacare.24.7.1226

J. Rosenstock, D. Einhorn, K. Hershon, and S. Yu, Efficacy and safety of pioglitazone in type 2 diabete : a randomized, placebo-controlled study in patients receiving stable insulin therapy, Int J Clin Pract, vol.56, pp.251-258, 2002.

R. Goldberg, D. Kendall, M. Deeg, J. Buse, A. Zagar et al., A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia, Diabetes Care, vol.28, issue.7, pp.1547-1554, 2005.
DOI : 10.2337/diacare.28.7.1547

Y. Guan, C. Hao, D. Cha, R. Rao, W. Lu et al., Thiazolidinediones expand body fluid volume through PPAR?? stimulation of ENaC-mediated renal salt absorption, Nature Medicine, vol.6, issue.8, pp.861-867, 2005.
DOI : 10.1023/A:1018401015497

M. Emoto, T. Anno, Y. Sato, K. Tanabe, S. Okuya et al., Troglitazone Treatment Increases Plasma Vascular Endothelial Growth Factor in Diabetic Patients and Its mRNA in 3T3-L1 Adipocytes, Diabetes, vol.50, issue.5, pp.1166-77, 2001.
DOI : 10.2337/diabetes.50.5.1166

URL : http://diabetes.diabetesjournals.org/content/diabetes/50/5/1166.full.pdf

E. Muayed, M. Lavis, V. Safi, H. Fuentes, and F. , Use of glitazones in cardiac patients: a case for B-type natriuretic peptide monitoring?, The American Journal of Cardiology, vol.93, issue.5, pp.600-602, 2004.
DOI : 10.1016/j.amjcard.2003.11.025

G. Fonarow, Approach to the management of diabetic patients with heart failure: Role of thiazolidinediones, American Heart Journal, vol.148, issue.4, pp.551-559, 2004.
DOI : 10.1016/j.ahj.2004.04.033

J. Buse, C. Rubin, R. Frederich, K. Viraswami-appanna, K. Lin et al., Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes

B. Goldstein, J. Rosenstock, and D. Anzalone, Tesaglitazar improves glucose and lipid abnormalities in patients with type 2 diabetes, Diabetes, vol.54, p.21, 2005.

S. Nissen, K. Wolski, and E. Topol, Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus, JAMA, vol.294, issue.20, pp.2581-2587, 2005.
DOI : 10.1001/jama.294.20.joc50147

. Zhouyt, P. Grayburn, and A. Karim, Lipotoxic heart disease in obese rats: implications for human obesity, Proc Natl Acad Sei, vol.97, pp.1784-1793, 2000.

H. Takano, T. Nagai, M. Asakawa, T. Toyozaki, T. Oka et al., Peroxisome Proliferator-Activated Receptor Activators Inhibit Lipopolysaccharide-Induced Tumor Necrosis Factor-?? Expression in Neonatal Rat Cardiac Myocytes, Circulation Research, vol.87, issue.7, pp.596-602, 2000.
DOI : 10.1161/01.RES.87.7.596

T. Delea, J. Edelsberg, M. Hagiwara, G. Oster, and L. Phillips, Use of Thiazolidinediones and Risk of Heart Failure in People With Type 2 Diabetes: A retrospective cohort study, Diabetes Care, vol.26, issue.11, pp.2983-2992, 2003.
DOI : 10.2337/diacare.26.11.2983

S. Inzucchi, F. Masoudi, Y. Wang, M. Kosiborod, J. Foody et al., Insulin-Sensitizing Antihyperglycemic Drugs and Mortality After Acute Myocardial Infarction: Insights from the National Heart Care Project, Diabetes Care, vol.28, issue.7, pp.1680-1689, 2005.
DOI : 10.2337/diacare.28.7.1680

URL : http://care.diabetesjournals.org/content/diacare/28/7/1680.full.pdf

A. Karter, A. Ahmed, J. Liu, H. Moffet, and M. Parker, Pioglitazone initiation and subsequent hospitalization for congestive heart failure, Diabetic Medicine, vol.56, issue.8, pp.986-93, 2005.
DOI : 10.1056/NEJM199312303292710

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3557913/pdf

F. Masoudi, S. Inzucchi, Y. Wang, E. Havranek, J. Foody et al., Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: An observational study, Circulation, vol.11, pp.583-90, 2005.

S. Maru, G. Koch, M. Stender, D. Clark, L. Gibowski et al., Antidiabetic Drugs and Heart Failure Risk in Patients With Type 2 Diabetes in the U.K. Primary Care Setting, Diabetes Care, vol.28, issue.1, pp.20-26, 2005.
DOI : 10.2337/diacare.28.1.20

D. Bell, Heart Failure: The frequent, forgotten, and often fatal complication of diabetes, Diabetes Care, vol.26, issue.8, pp.2433-2474, 2003.
DOI : 10.2337/diacare.26.8.2433

W. Kannel, M. Gee, and D. , Diabetes and Cardiovascular Disease, JAMA, vol.241, issue.19, pp.2035-2041, 1979.
DOI : 10.1001/jama.1979.03290450033020

W. Aronow and C. Ahn, Incidence of Heart Failure in 2,737 Older Persons With and Without Diabetes Mellitus, Chest, vol.115, issue.3, pp.867-875, 1999.
DOI : 10.1378/chest.115.3.867

I. Stratton, A. Adler, H. Neil, D. Matthews, S. Manley et al., Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, BMJ, vol.321, issue.7258, pp.405-412, 2000.
DOI : 10.1136/bmj.321.7258.405

J. Swan, S. Anker, C. Walton, I. Godsland, A. Clark et al., Insulin Resistance in Chronic Heart Failure: Relation to Severity and Etiology of Heart Failure, Journal of the American College of Cardiology, vol.30, issue.2, pp.527-559, 1997.
DOI : 10.1016/S0735-1097(97)00185-X

J. Beckman, M. Creager, and P. Libby, Diabetes and Atherosclerosis, JAMA, vol.287, issue.19, pp.2570-81, 2002.
DOI : 10.1001/jama.287.19.2570

W. Tang, G. Francis, B. Hoogwerf, and J. Young, Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure, Journal of the American College of Cardiology, vol.41, issue.8, pp.1394-1398, 2003.
DOI : 10.1016/S0735-1097(03)00159-1

R. Malone, D. Dewalt, M. Pignone, and T. Ives, Is the tolerability of long-term thiazolidinedione therapy overstated?, Journal of the American College of Cardiology, vol.42, issue.7, pp.1334-1334, 2003.
DOI : 10.1016/S0735-1097(03)00995-1

J. Dormandy, B. Charbonnel, D. Eckland, E. Erdmann, M. Massi-benedetti et al., Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial, The Lancet, vol.366, issue.9493, pp.1279-89, 2005.
DOI : 10.1016/S0140-6736(05)67528-9

S. Kahn, S. Haffner, M. Heise, W. Herman, R. Holman et al., Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy, New England Journal of Medicine, vol.355, issue.23, pp.2427-2470, 2006.
DOI : 10.1056/NEJMoa066224

J. Pogue, P. Sheridan, and N. Dinccag, Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose : A randomised controlled trial, Lan cet, vol.368, pp.1096-105, 2006.

E. Erdmann, J. Dormandy, B. Charbonnel, M. Massi-benedetti, I. Moules et al., The Effect of Pioglitazone on Recurrent Myocardial Infarction in 2,445 Patients With Type 2 Diabetes and Previous Myocardial Infarction, Journal of the American College of Cardiology, vol.49, issue.17, pp.1772-80, 2007.
DOI : 10.1016/j.jacc.2006.12.048

D. Riche, R. Valderrama, and N. Henyan, Thiazolidinediones and Risk of Repeat Target Vessel Revascularization Following Percutaneous Coronary Intervention: A meta-analysis, Diabetes Care, vol.30, issue.2, pp.384-392, 2007.
DOI : 10.2337/dc06-1854

W. Sauer, A. Cappola, J. Berlin, and S. Kimmel, Insulin Sensitizing Pharmacotherapy for Prevention of Myocardial Infarction in Patients With Diabetes Mellitus, The American Journal of Cardiology, vol.97, issue.5, pp.651-654, 2006.
DOI : 10.1016/j.amjcard.2005.09.106

C. Johannes, S. Quinn, C. Korn, J. Cutone, and J. Seeger, The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy, Pharmacoepidemiology and Drug Safety, vol.15, issue.5, pp.504-512, 2007.
DOI : 10.1093/oxfordjournals.aje.a010011

S. Nissen and K. Wolski, Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes, New England Journal of Medicine, vol.356, issue.24, pp.2457-71, 2007.
DOI : 10.1056/NEJMoa072761

B. Psaty and C. Furberg, Rosiglitazone and Cardiovascular Risk, New England Journal of Medicine, vol.356, issue.24, pp.2522-2526, 2007.
DOI : 10.1056/NEJMe078099

A. Lincoff, K. Wolski, S. Nicholls, and S. Nissen, Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus, JAMA, vol.298, issue.10, pp.1180-1188, 2007.
DOI : 10.1001/jama.298.10.1180

Y. Masubuchi, Metabolic and non-metabolic factors determining troglitazone hepatotoxicity : a review. Drng metab pharmacokinet 2006 oct, pp.347-56
DOI : 10.2133/dmpk.21.347

H. Lebovitz, M. Kreider, and M. Freed, Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials: Evidence that rosiglitazone does not cause hepatic dysfunction, Diabetes Care, vol.25, issue.5, pp.815-836, 2002.
DOI : 10.2337/diacare.25.5.815

A. Scheen, Thiazolidinediones and liver toxicity. Diabetes Metab, 2001.

L. May, J. Lefkowitch, M. Krarn, and D. Rubin, Mixed Hepatocellular???Cholestatic Liver Injury after Pioglitazone Therapy, Annals of Internal Medicine, vol.136, issue.6, pp.449-52, 2002.
DOI : 10.7326/0003-4819-136-6-200203190-00008

K. Maeda, Hepatocellular Injury in a Patient Receiving Pioglitazone, Annals of Internal Medicine, vol.135, issue.4, p.306, 200121.
DOI : 10.7326/0003-4819-135-4-200108210-00029

URL : http://annals.org/data/journals/aim/19989/0000605-200108210-00015.pdf

A. Pinto, O. Curnrnings, and N. Chalasani, Severe but Reversible Cholestatic Liver Injury after Pioglitazone Therapy, Annals of Internal Medicine, vol.137, issue.10, p.857, 2002.
DOI : 10.7326/0003-4819-137-10-200211190-00023

M. Chase and J. Yarze, Pioglitazone-associated fulminant hepatic failure, The American Journal of Gastroenterology, vol.132, issue.2, pp.502-505, 2002.
DOI : 10.1111/j.1572-0241.2000.01707.x

H. Bonkovsky, R. Azar, S. Bird, G. Szabo, and B. Banner, Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone, Digestive Diseases and Sciences, vol.47, issue.7, pp.1632-1639, 2002.
DOI : 10.1023/A:1015895925374

J. Al-salrnan, H. Arjornand, D. Kemp, and M. Mittal, Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case Report, Annals of Internal Medicine, vol.132, issue.2, pp.121-125, 2000.
DOI : 10.7326/0003-4819-132-2-200001180-00006

L. Forman, D. Sirnrnons, and R. Diarnond, Hepatic Failure in a Patient Taking Rosiglitazone, Annals of Internal Medicine, vol.132, issue.2, pp.118-139, 2000.
DOI : 10.7326/0003-4819-132-2-200001180-00005

R. Rajagopalan, S. Iyer, and A. Perez, Comparaison of pioglitazone with other antidiabetic dugs for associated incidence of liver failure : no evidence of increased risk of liver failure with pioglitazone. Diabetes Obes Metab, pp.161-170, 2005.

A. Scheen, Hepatotoxicity with Thiazolidinediones, Drug Safety, vol.22, issue.7, pp.873-88, 2001.
DOI : 10.2165/00002018-200124120-00002

S. J. Evans, P. C. Waller, and S. Davis, Use of prop011ional reporting ratios (PRRs) for signal generation frorn spontaneous adverse drug reaction reports

E. P. Van-puijenbroek, A. C. Egberts, E. R. Heerdink, and . G. Leufkensh, Detecting drugdrug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs, Eur J Clin Pharmacol, vol.56, pp.9-10733, 2000.

E. Robert and P. Guiraud, Materna! valproic acid and congenital neural tube defects, Lancet, vol.2, p.937, 1982.

B. H. Stricker and J. G. Tjissen, Serum sickness-like reactions to cefaclor, Journal of Clinical Epidemiology, vol.45, issue.10, pp.1177-1184, 1992.
DOI : 10.1016/0895-4356(92)90158-J

O. Spigset and K. Hedenmaim, Hyponatremia m relation to treatment with antidepressants : a survey of reports in the World Health Organisation . Database for spontaneous reporting of adverse drug reactions, Pharmacotherapy, vol.17, pp.348-352, 1997.

F. Thiessard, E. Roux, G. Miremont-salame, A. Fourrier-reglat, F. Haramburu et al., Trends in Spontaneous Adverse Drug Reaction Reports to the French Pharmacovigilance System (1986???2001), Drug Safety, vol.46, issue.8, pp.731-771, 1986.
DOI : 10.2165/00002018-200528080-00007

URL : https://hal.archives-ouvertes.fr/hal-00396045

M. Gony, M. Lapeyre-mestre, and J. Montastruc, Risk of Serious Extrapyramidal Symptoms in Patients With Parkinson's Disease Receiving Antidepressant Drugs: A Pharmacoepidemiologic Study Comparing Serotonin Reuptake Inhibitors and Other Antidepressant Drugs, Clinical Neuropharmacology, vol.26, issue.3, pp.142-147, 2003.
DOI : 10.1097/00002826-200305000-00007

P. Centres, Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients, Eur J Clin Pharmacol, vol.62, issue.3, pp.243-252, 2006.

N. Moore, . Kreft-jais, F. Haramburu, C. Noblet, M. Andrejak et al., Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database, British Journal of Clinical Pharmacology, vol.44, issue.5, pp.513-521, 1997.
DOI : 10.1046/j.1365-2125.1997.00615.x

G. Rodriguez, L. Hernandez-diaz, and S. , Nonsteroidal anti-inflammatory drugs as a trigger of clinical heart failure, Epidemiology, vol.14, issue.2, pp.240-246, 2003.

S. Inzucchi, Metformin in Heart Failure, Diabetes Care, vol.30, issue.12, pp.2585-2592, 2005.
DOI : 10.2337/dc07-1686

S. Kenchaiah, J. Evans, D. Levy, P. Wilson, E. Benjamin et al., Obesity and the Risk of Heart Failure, New England Journal of Medicine, vol.347, issue.5, pp.305-318, 2002.
DOI : 10.1056/NEJMoa020245

W. Tang, Do thiazolidinediones cause heart failure? A critical review., Cleveland Clinic Journal of Medicine, vol.73, issue.4, pp.390-397, 2006.
DOI : 10.3949/ccjm.73.4.390

J. Stamler, . Vaccaro-0, J. Neaton, and D. Wentworth, Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial, Diabetes Care, vol.16, issue.2, pp.434-478, 1993.
DOI : 10.2337/diacare.16.2.434

G. Aithal and C. Day, Nonsteroidal anti-inflammatory drug-induced hepatotoxicity.Clin Liver Dis, pp.563-75, 2007.
DOI : 10.1016/j.cld.2007.06.004

A. Nationale-d, Accréditation et d'Evaluation en Santé, 2003.

D. Simon and E. Eschwege, Données épidémiologiques sur le diabète de type 2, BEH, pp.20-21, 2002.

P. Chanson, J. Timsit, and B. Charbonnel, Données actualisées de l'UKPDS ; implication pour la prise en charge des patients diabétiques de type 2, MT Endocrinologie, vol.3, pp.207-216, 2000.

S. Berthet, S. Grolleau, C. Brefel-courbon, J. Montastruc, and M. Lapeyre-mestre, Prevalence of diabetes in france and Drug use: Study based on the French Pharmacovigilance Database. Therapie, Novembre-Decembre, vol.62, issue.6, pp.483-488, 2007.

S. Lugardon, K. Desboeuf, P. Femet, J. Montastruc, and M. Lapeyre-mestre, Assessing the prevalence of adverse drug reactions in a French University Hospital: a capturerecapture study using data from PMSI and the French pharmacovigilance database

S. Berthet, J. Montastruc, and M. Lapeyre-mestre, Drug safety of Thiazolidinediones in France. Fundamental & Clinical Pharmacology. Abstracts of the P2T Congres de Physiologie, Annexe, vol.1, issue.22, pp.1-102, 2008.

S. Berthet, S. Grolleau, C. Brefel-courbon, J. Montastruc, and M. Lapeyre-mestre, Prevalence of diabetes in france and Drug use: Study based on the French Pharmacovigilance Database. Therapie, Novembre-Decembre, vol.62, issue.6, pp.483-488, 2007.